Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Milestone

You Said:

Even if Rule 14a-11 was available next year, it would take a minimum of 3 more years to get a majority of shareholder nominees on the BoD, 4 if increased to 7 members. If the Rule is not applicable, one is looking at 6 or 7 more years, by which time most patents will have expired.

Additionally, PTSC could amend director qualification standards whereby prior experience as a director of a publicly traded company is a pre-requisite for inclusion on the proxy.

It has been discussed in prior posts that one or more board members (perhaps Flowers as well) read this message board. Are you sharing what you know to be ideas being discussed by the BoD or as Pete suggested, are you merely giving them ideas?

You avoided answering my questions in a previous post, so I will ask again.

Are you a member of the BoD of PTSC or an employee of the company?

Are you related to, employed by or affiliated in any way with Eric Swartz or his partners, David Pohl, Carlton Johnson, Gloria Felcyn or Helmut Falk?

Also, I would like your opinion; based on the pending decision of the SEC, if there is a favorable decision for Pete Lozano, what will happen next?

Thanks much,

Laurie

Share
New Message
Please login to post a reply